These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38053165)

  • 1. Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development.
    Nikolaienko O; Eikesdal HP; Ognedal E; Gilje B; Lundgren S; Blix ES; Espelid H; Geisler J; Geisler S; Janssen EAM; Yndestad S; Minsaas L; Leirvaag B; Lillestøl R; Knappskog S; Lønning PE
    Genome Med; 2023 Dec; 15(1):104. PubMed ID: 38053165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutional
    Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters.
    Al-Moghrabi N; Al-Showimi M; Al-Yousef N; Al-Shahrani B; Karakas B; Alghofaili L; Almubarak H; Madkhali S; Al Humaidan H
    Clin Epigenetics; 2018 Jul; 10(1):99. PubMed ID: 30049288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan.
    Muhammad N; Azeem A; Bakar MA; Prajzendanc K; Loya A; Jakubowska A; Hamann U; Rashid MU
    Breast Cancer Res Treat; 2023 Nov; 202(2):377-387. PubMed ID: 37528266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement.
    Schwartz M; Ibadioune S; Vacher S; Villy MC; Trabelsi-Grati O; Le Gall J; Caputo SM; Delhomelle H; Warcoin M; Moncoutier V; Bourneix C; Boutry-Kryza N; De Pauw A; Stern MH; Buecher B; Mouret-Fourme E; Colas C; Stoppa-Lyonnet D; Masliah-Planchon J; Golmard L; Bieche I
    Breast; 2024 Feb; 73():103620. PubMed ID: 38096711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
    Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    Morizono A; Tanabe M; Ikemura M; Sasaki T; Ushiku T; Seto Y
    J Hum Genet; 2021 Aug; 66(8):785-793. PubMed ID: 33640902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
    Hansmann T; Pliushch G; Leubner M; Kroll P; Endt D; Gehrig A; Preisler-Adams S; Wieacker P; Haaf T
    Hum Mol Genet; 2012 Nov; 21(21):4669-79. PubMed ID: 22843497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutional Mosaic Epimutations - a hidden cause of cancer?
    Lønning PE; Eikesdal HP; Løes IM; Knappskog S
    Cell Stress; 2019 Mar; 3(4):118-135. PubMed ID: 31225507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
    Al-Moghrabi N; Nofel A; Al-Yousef N; Madkhali S; Bin Amer SM; Alaiya A; Shinwari Z; Al-Tweigeri T; Karakas B; Tulbah A; Aboussekhra A
    BMC Cancer; 2014 Nov; 14():830. PubMed ID: 25403427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
    Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.